In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Hutchison China MediTech Ltd. Trade Record

NASDAQ:HCM Hutchison China MediTech Ltd stock gains 10.57% Exit Nov 28, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart HCM Nov 13, 2017, priceSeries
About Hutchison China MediTech Ltd

Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides drug research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and health-related consumer products under the Bai Yun Shan and Shang Yao brands. It also develops clinical drug candidates, including AZD6094 that is in Phase Ib clinical trial for treating non-small cell lung and gastric cancer; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib, a Phase Ib clinical trial product for neuroendocrine tumors and thyroid cancers; and HMPL-523, a preclinical stage product for the treatment of immunology, rheumatoid arthritis, lupus, and hematological cancers. In addition, the company is developing Epitinib for the treatment of non-small cell lung cancer; Theliatinib, a Phase I clinical trial product for the treatment of solid tumors; HMPL-689, a preclinical stage product for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn's disease; and HMPL-453 that is in preclinical stage for the treatment of solid tumors. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Trade Information
Trade Type
LONG
ReliabilityScore™
85.00
Entry Date
Nov 13, 2017
Entry Price
30.54
Sell Date
Nov 28, 2017
Sell Price
33.77
Net Gain
10.57%
Hold Time
10 Trading Days